Diagnostic accuracy of sensitive or high-sensitive troponin on presentation for myocardial infarction: a meta-analysis and systematic review

Sandeep Khosla
Ankur Sethi
Anurag Bajaj
Rohit R Arora
Gurveen Malhotra

Background: Recently, high-sensitive troponin (hsTrop) assays consistent with professional societies’ recommendations became available. We aimed to summarize the evidence on the diagnostic accuracy of hsTrop on presentation.

Methods: We searched electronic databases for studies evaluating the diagnostic accuracy of hsTrop in suspected acute coronary syndrome (ACS) patients. Random effect meta-analyses and meta-regression were performed. Primary and secondary analyses were restricted to studies using conventional Trop and hsTrop in the reference standard, respectively.

Results: Fifteen studies with a total of 8,628 patients met the inclusion criteria for the primary analysis. hsTrop T (Hoffman-La Roche Ltd) and hsTrop I (Siemens) had sensitivities of 0.89 (95% confidence interval [CI]: 0.86–0.91) and 0.90 (95% CI: 0.87–0.92) and specificities of 0.79 (95% CI: 0.77–0.80) and 0.89 (95% CI: 0.87–0.90), respectively. There was no statistically significant difference in the area under the curve between hsTrop (95% CI: 0.920) and conventional Trop (95% CI: 0.929) at the 99th percentile (P=0.62). hsTrop at the level of detection had a sensitivity of 0.97 (95% CI: 0.96–0.98) and a specificity of 0.41 (95% CI: 0.40–0.42). The studies using a cut-off at coefficient of variance <10% as opposed to the 99th percentile for the conventional assay used for diagnosis reported higher diagnostic accuracy (relative diagnostic odds ratio =2.13, P=0.02). Five studies were included in the secondary analysis; hsTrop T (Hoffman-La Roche Ltd) had a sensitivity of 0.91 (95% CI: 0.89–0.93) and a specificity of 0.67 (95% CI: 0.63–0.70). There was significant heterogeneity among the studies.

Conclusion: hsTrop have excellent diagnostic accuracy for myocardial infarction on presentation, but may not outperform conventional Trop assays. The variation among the studies can be explained, in part, by the cut-off used for conventional Trop assays.

Keywords: high-sensitive troponin T, high-sensitive troponin I, sensitivity, specificity, level of detection

Background
Each year in the US, more than seven million people visit the emergency department with complaints of chest pain and related symptoms. Many such patients require further evaluation including cardiac biomarkers. Cardiac troponins T or I (Trop T or I) are the preferred biomarkers for the evaluation of such patients with suspected acute coronary syndrome (ACS). Trop T or I not only help in the rapid diagnosis of acute myocardial infarction (AMI), but also in risk stratification and selection of an appropriate treatment strategy. The European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation (ESC/ACC/AHA/WHF) task force consensus document recommends an assay-specific cut-off of 99th percentile of...
a normal healthy population as the decision level, in addition to a rise and fall pattern, for the diagnosis of AMI. In order to reliably detect rise and fall, assays with a coefficient of variation (CV) <10% at the 99th percentile are considered to have optimal precision. Contemporary Trop assays lack such a precision at the 99th percentile, and therefore suffer from reduced sensitivity, especially during the early hours of AMI. To fulfill these criteria, sensitive or high-sensitive troponin (sTrop or hsTrop) assays with improved sensitivity and precision (CV <10% at the 99th percentile) have been developed. Initial studies have reported improved diagnostic accuracy of sTrop/hsTrop (s/hsTrop) assays on presentation to the emergency room at the recommended 99th percentile cut-off.

Subsequent studies have proposed a novel cut-off at the level of detection (LOD) in order to achieve 100% sensitivity on the initial evaluation and rapidly rule out patients with symptoms suggestive of ACS. Although a test with high sensitivity is desired in the emergency room setting, the elevations in Trop, as measured by the s/hsTrop assays in conditions other than AMI, may significantly compromise its specificity. In order to synthesize the evidence on currently available s/hsTrop assays, we undertook a systematic review and meta-analysis to assess the diagnostic accuracy of s/hsTrop on initial presentation in patients with symptoms suggestive of ACS.

Methods

We systematically searched PubMed/MEDLINE and the EMBASE database for clinical studies evaluating the diagnostic accuracy of s/hsTrop assays in unselected patient populations suspected of ACS. The following keywords were used: “high-sensitive/sensitivity troponin”, “Roche troponin”, “Abbott troponin”, and “Siemens troponin”. The reference list of included studies and relevant review articles were hand-searched to identify additional studies. Citations with manuscripts published in peer-reviewed journals were included. Conference abstracts were excluded due to the inability to assess the relevant study characteristics. No language restrictions were imposed. The last search was performed on November 9, 2012.

For the purpose of this review, s/hsTrop assays were defined as assays with: 1) LOD <99th percentile of the healthy population and 2) CV ≤10% at the 99th percentile for the assay.

The following inclusion criteria were used: prospective, retrospective, or observational studies evaluating the diagnostic accuracy of s/hsTrop assays, as defined above, on initial presentation in unselected patients presenting with symptoms suggestive of ACS. In addition, the final diagnosis was adjudicated by a contemporary reference standard that comprised a review of the clinical data, serial Trop testing, and available supplementary investigations to diagnose or exclude AMI (or ACS) in accordance with the existing guidelines.

Exclusion criteria: studies only evaluating specific patients such as those with negative biomarkers on presentation, abnormal electrocardiogram, or undergoing invasive therapy were excluded. Also, studies using creatine kinase/creatinine kinase myocardial band for the diagnosis of AMI were excluded.

Data extraction and synthesis

Two authors (AS and AB) independently assessed all studies for inclusion in the systematic review and meta-analysis. Data on study characteristics – mean/median age, % males, inclusion/exclusion criteria, and adjudication of diagnosis – were extracted from the included studies (Table S1). The enrollment period and study sites for the data collection were specifically noted to prevent duplication. In the presence of more than one study from the same site and enrollment period, the study with the higher number of patients and latest publication date was included. The studies reporting accuracy of more than one s/hsTrop assay were treated as separate datasets. Among other study characteristics, inclusion of patients with ST elevation myocardial infarction (STEMI), dialysis, and prevalence of coronary artery disease (CAD) were noted. If the prevalence of CAD was not reported, then the most prevalent surrogate, ie, angina, myocardial infarction, or coronary revascularization was used. The cut-off value used for both s/hsTrop and conventional Trop assays was noted. There was a provision of third author evaluation in the case of disagreement regarding study inclusion or extracted characteristics, but no significant discordance was encountered.

The primary quantitative analysis was restricted to studies evaluating diagnostic accuracy for AMI using conventional Trop testing in the reference standard. A systematic review of studies evaluating diagnostic accuracy for ACS instead of AMI was reported separately. A secondary quantitative and qualitative analysis was performed on the studies evaluating diagnostic accuracy of s/hsTrop for AMI using serial s/hsTrop testing instead of conventional Trop in the reference standard.

Statistical analysis

Absolute numbers of true-positive, true-negative, false-positive, and false-negative were extracted or calculated for the individual studies. From the extracted data pooled, sensitivity, specificity, and negative and positive likelihood ratio
were calculated using the DerSimonian and Laird method (random effect model). As studies with the same diagnostic cut-off, ie, 99th percentile or LOD were used to calculate pooled estimates, threshold analysis was not undertaken.

Heterogeneity between studies was assessed using Cochran’s Q test and $I^2$ (Inconsistency index). The source of heterogeneity among the studies was explored by performing a meta-regression of study characteristics on the diagnostic odds ratio (DOR) by using the restricted maximum likelihood method weighted by the inverse of study variance and inclusion of threshold effect in the model.

The summary receiver operating curve (SROC) was estimated with the area under the curve (AUC) as the measure of diagnostic accuracy. An AUC of 0.5 indicated poor discrimination, whereas value of 1 suggested perfect discrimination between those with and without disease. The curve was plotted on the basis of change in DOR using the DerSimonian and Laird method. The areas under the curve were compared using two-tailed t-tests. A $P$-value $<0.05$ was considered statistically significant. Statistical analysis was performed using Review Manager (RevMan; v5.2; The Nordic Cochrane Centre, Copenhagen, Denmark) and Meta-DiSc (v1.4; Clinical Biostatistics Unit, Ramon y Cajal Hospital, Madrid, Spain).

The Review Manager was used for quality assessment of included studies based on the QUADAS (Quality Assessment tool for Diagnostic Accuracy Studies) questionnaire.

Results

Fifteen studies with a total of 8,628 patients met the inclusion criteria for the primary analysis as shown in Figure 1 – eight studies with 3,115 patients used hsTrop T, six studies with 4,415 patients used s/hsTrop I, and one study with 1,098 patients used both hsTrop T and sTrop I. Among these studies, ten studies also reported on the diagnostic accuracy of conventional Trop assays on initial presentation at a cut-off of 99th percentile. The mean/median age was 54–67.6 years, and 49.2%–71.3% patients were male. Other relevant study characteristics are shown in Table S1. All hsTrop T studies used the assay manufactured by Roche (Roche High-Sensitive Troponin T; Hoffman-La Roche Ltd, Basel, Switzerland). Out of the seven studies on s/hsTrop I, four used Trop I Ultra (Siemens Healthcare Diagnostics, Erlangen, Germany), one used Architect STAT High-Sensitive Trop (Abbott Laboratories, Abbott Park, IL, USA), one used VITROS Trop I assay (Ortho-Clinical Diagnostics; Johnson & Johnson, New Brunswick, NJ, USA), and one used Singulex Erenna Trop I (Alameda, CA, USA). Two additional studies that reported diagnostic accuracy of s/hsTrop for ACS only were identified (Table S1). Seven studies reported diagnostic accuracy of hsTrop using serial s/hsTrop assays in the reference standard and were included in the secondary analysis (Table S2).

hsTrop T

Eight out of the nine studies reported diagnostic accuracy of hsTrop T on presentation at a 99th percentile cut-off of a healthy population. Kurz et al\(^9\) used a different diagnostic cut-off for hsTrop T, and therefore, was not included in the calculation of pooled point estimates. The pooled sensitivity and specificity were 0.885 (95% CI: 0.863–0.905, $\chi^2=32.87$, $P=0.001$, $I^2=78.7%$) and 0.783 (95% CI: 0.768–0.797, $\chi^2=47.5$, $P=0.001$, $I^2=85.3%$), respectively, as shown in Figure 2A. The pooled positive and negative likelihood ratios were 3.999 (95% CI: 3.360–4.760, $\chi^2=38.6$, $P=0.001$, $I^2=81.9%$) and 0.137 (95% CI: 0.092–0.205, $\chi^2=27.82$, $P<0.001$, $I^2=74.8%$), respectively (Table 1A). There was significant heterogeneity among the studies.

s/hsTrop I

The assay types were more variable in the s/hsTrop I studies. Therefore, in addition to cumulative point estimates, a subgroup analysis of studies using a sensitive assay – Siemens Trop I Ultra – was performed. The pooled sensitivity and specificity of all s/hsTrop I studies at a 99th percentile cut-off were 0.867 (95% CI: 0.845–0.887, $\chi^2=43.46$, $P<0.001$, $I^2=86.2%$) and 0.879 (95% CI: 0.869–0.888, $\chi^2=80.34$, $P<0.001$, $I^2=92.5%$), respectively. The pooled sensitivity and specificity of the studies using Siemens trop I Ultra were 0.899 (95% CI: 0.874–0.886, $\chi^2=21.62$, $P<0.001$, $I^2=86.1%$) and 0.886 (95% CI: 0.874–0.898, $\chi^2=19.26$, $P<0.001$, $I^2=84.4%$), respectively, as shown in Figure 2B and Table 1. The pooled positive and negative likelihood ratios for this subgroup were 6.30 (95% CI: 4.400–9.022, $\chi^2=27$, $P<0.001$, $I^2=88.9%$) and 0.135 (95% CI: 0.067–0.269, $\chi^2=20.37$, $P<0.001$, $I^2=85.3%$), respectively, as shown in Table 1A. There was significant heterogeneity among the studies for all pooled estimates.

s/hsTrop at the LOD

Nine studies/substudies reported diagnostic accuracy of s/hsTrop at the cut-off of LOD on presentation. Reiter et al\(^11\) did not report diagnostic accuracy at LOD. However, a prior publication from the same cohort did\(^6\) and was included in the current analysis. The pooled sensitivity and specificity were 0.974 (95% CI: 0.963–0.983, $\chi^2=44.4$, $P<0.001$, $I^2=82%$) and 0.410 (95% CI: 0.396–0.424, $\chi^2=533.2$, $P<0.001$, $I^2=94.1%$), respectively.
P<0.001, \( R^2 = 98.5\%\), respectively. The pooled positive and negative likelihood ratios were 1.646 (95% CI: 1.337–2.027, \( \chi^2 = 609.87, P<0.001, R^2 = 98.7\% \)) and 0.079 (95% CI: 0.042–0.148, \( \chi^2 = 17.45, P=0.026, R^2 = 54.1\% \)), respectively (Table 1).

**Effect of study covariates**

To explore the heterogeneity among the studies, meta-regression analysis of four study level covariates: inclusion of patients with STEMI and dialysis, prevalence of CAD, and cut-off of conventional assays used to diagnose AMIs on the DOR was performed. There was no association between diagnostic accuracy and the other three study characteristics, but use of a cut-off CV <10% for the conventional assay instead of the 99th percentile significantly improved the diagnostic accuracy of s/hsTrop on presentation as shown in Table 1B.

**Comparison of conventional and hsTrop**

Among the included studies, ten studies reported the diagnostic accuracy of conventional trop assays on presentation. The SROC of conventional Trop assays, s/hsTrop assays at a cut-off of 99th percentile, and the LOD is shown in Figure 3. There was

---

**Figure 1** Study selection flow chart.

**Abbreviations:** hsTrop, high-sensitive troponin; MB, myocardial band; MI, myocardial infarction.
no statistically significant difference between the AUC of conventional Trop and s hsTrop at two different cut-offs.

ACS
Two studies not included in the primary analysis reported diagnostic accuracy for ACS only (Table S1). Also, Keller et al19 and Reiter et al21 reported diagnostic accuracy for ACS in addition to AMI. As shown in Figure S1, the sensitivity ranged 0.56–0.77 and the specificity ranged 0.76–0.94.

s hsTrop for adjudication of diagnosis
Seven additional studies that used serial s hsTrop testing in the reference standard, instead of conventional Trop, to diagnosis the AMI were identified (Table S2). In addition to conventional assays, Christ et al8 and Melki et al20 reported diagnostic accuracy on presentation using serial hsTrop T testing to diagnose AMI. Clearly, the outcomes of these studies suffer from incorporation bias. Out of these nine studies, seven used hsTrop T (Hoffman-La Roche Ltd) and two used trop I Ultra (Siemens Healthcare Diagnostics). The studies were very heterogeneous in terms of inclusion and exclusion criteria, as well as diagnostic cut-off. Kelly27 and Khan et al28 excluded patients with any alternate diagnosis and Scharnhorst et al13 used clinical diagnosis to adjudicate the AMI. The pooled sensitivity and specificity for hsTrop T (Hoffman-La Roche Ltd) on admission, after exclusion of

Table I (A) Pooled estimates of diagnostic accuracy for myocardial infarction of studies included in primary analysis; (B) results of meta-regression analysis of study level covariates on diagnostic odds ratio

(A) Outcome | hsTrop T (Roche) at 99th percentile | hsTrop I (Siemens) at 99th percentile | hsTrop I or T at LOD
--- | --- | --- | ---
Sensitivity (95% CI) | 0.885 (0.863–0.905) | 0.899 (0.874–0.921) | 0.974 (0.963–0.983)
Specificity (95% CI) | 0.783 (0.768–0.797) | 0.886 (0.874–0.898) | 0.410 (0.395–0.424)
Positive likelihood ratio (95% CI) | 3.999 (3.360–4.760) | 6.300 (4.400–9.022) | 1.646 (1.337–2.026)
Negative likelihood ratio (95% CI) | 0.137 (0.092–0.205) | 0.135 (0.067–0.269) | 0.079 (0.042–0.148)

(B) Study variable | RDOR | 95% CI | P-value
--- | --- | --- | ---
Inclusion of STEMI | 1.35 | 0.58–3.16 | 0.469
Exclusion of patients with dialysis | 1.63 | 0.73–3.67 | 0.218
Prevalence of CAD | 0.11 | 0.00–10.62 | 0.329
Diagnostic cut-off <10% CV versus 99th percentile | 2.15 | 1.10–4.21 | 0.027

Abbreviations: CAD, coronary artery disease; CI, confidence interval; CV, coefficient of variance; hsTrop, high-sensitive troponin; LOD, level of detection; RDOR, relative diagnostic odds ratio; STEMI, ST elevation myocardial infarction; Roche, Hoffman-La Roche Ltd; Siemens, Siemens Healthcare Diagnostics.
the studies were thought to have included a representative spectrum of patients presenting to the emergency department or admitted to the hospital, except for the studies by Aldous et al, Bhardwaj et al, Casals et al, and Schreiber et al, because of the use of a convenience sample, incompletely defined inclusion criteria, or unrealistic exclusion criteria. The index test was not blinded in the study by Christ et al. No studies reported intermediate or uninterpretable test results.

**Discussion**

The introduction of s/hsTrop assays with enhanced analytic performance, consistent with the recommendations of the ESC/ACCF/AHA/WHF consensus statement, is considered a major advancement in cardiovascular medicine. These assays are being used in many parts of the world, and are awaiting approval in the US and recently became approved for use in Canada. There is no standardized definition for the term hsTrop assays in the current literature, and it has been used for assays with variable properties. Most experts advocate the use of the term “hsTrop assays” for the assays that detect cardiac Trop in the majority of the reference population. Optimal precision, ie, CV <10% at the 99th percentile as defined by the ESC/ACCF/WHF consensus document is another desired characteristic feature of hsTrop assays. These features make s/hsTrop assays more sensitive compared to conventional Trop assays, especially near the upper reference limit. In the absence of a widely accepted definition of high-sensitive assays, we included studies evaluating assays with LOD at <99th percentile and CV ≤10% at the 99th percentile to be consistent with the ESC/AHA/ACCF/WHF consensus statement.

The 99th percentile is the cut-off recommended by the Joint ESC/ACCF/AHA/WHF task force as the decision limit, in addition to a rise and fall pattern, for the diagnosis of AMI. Similar to clinical practice, this decision limit is not consistently used for conventional Trop assays by contemporary studies evaluating the accuracy of s/hsTrop for the diagnosis of AMI. As pointed out previously, we found that studies using a cut-off of CV <10% (which is achieved at a level greater than the 99th percentile for all of the included conventional assays) instead of the 99th percentile, reported a higher diagnostic accuracy for s/hsTrop assays at presentation, as reflected by a relative diagnostic odds ratio of 2.15 (Table 1B). Although DOR does not allow separate weighing of true and false positive rates, it appears logical that the use of a cut-off higher than the 99th percentile will decrease the true positive rate for AMI; this may therefore enhance the diagnostic accuracy of s/hsTrop on presentation.
Further, comparing the AUC of SROC for s/hsTrop and conventional Trop on presentation at the 99th percentile cutoff failed to show any difference in supporting the current recommendation of using the 99th percentile, instead of at a CV level of <10%, as the decision limit.

Some authors have suggested that using a novel cut-off at the LOD for hsTrop on presentation can be an effective rapid rule out strategy, which is often desired in the emergency room setting. As shown in Table 1, at this novel cut-off, s/hsTrop assays provide an excellent sensitivity of 0.97. The negative predictive value will vary by the disease prevalence, but in general, may not reduce the historically reported rate of missed diagnosis of about 2%. Also, it is important to note that excellent sensitivity for the diagnosis of AMI may not be used to rule out ACS. Although no data was available for the novel cut-off, at the 99th percentile, s/hsTrop assays had a sensitivity ranging from 0.56–0.77; therefore, it certainly cannot be used as rapid rule out strategy underscoring the importance of complete clinical evaluation of the individual patient.

Evaluation of more sensitive assays against less sensitive reference standards is one of the limitations of the studies included in the primary analysis, as it may potentially inflate sensitivity with apparent loss of specificity. As Trop may be detected with s/hsTrop assays in some patients diagnosed as having unstable angina using conventional Trop assays, it may be useful to evaluate specificity for ACS rather than AMI. The specificity of s/hsTrop assays for ACS ranged 0.76–0.90 (Figure S1), which may not be an improvement over specificity for AMI (Table 1A). Furthermore, a systematic review of studies using s/hsTrop assays in the reference standard for the diagnosis of AMI (Table S2) shows that studies using very stringent exclusion criteria, ie, excluding all alternate diagnoses, cardiomyopathies, heart failure, etc, may achieve a specificity exceeding 0.9. However, the studies with a more representative spectrum of the patient population using contemporary diagnostic methods have lower specificity (Figure 3). Prior studies have shown that ACS patients testing positive for Trop by conventional assays derive additional benefit from glycoprotein IIb/IIIA inhibitors and anticoagulant therapies. Similarly, these patients appear to benefit from invasive therapy as opposed to conservative management. However, it remains unknown if ACS patients testing positive with hsTrop assays but negative with conventional Trop assays will benefit from these therapies.

s/hsTrop assays may detect elevation greater than at the 99th percentile in patients with non-ACS conditions including stable CAD and heart failure. Therefore, one of other major concerns with hsTrop assays is the false positive rates, which exceed 30% even when hsTrop assays were used in the reference standard (Figure 4). It is likely these patients who tested positive for elevated s/hsTrop in routine clinical practice will undergo additional testing that may not have been otherwise warranted. The cost incurred by this undesirable consequence of s/hsTrop assay use needs to be evaluated in future studies.

**Limitations**

This was a study level meta-analysis with significant heterogeneity among the studies not completely explained by meta-regression analysis. The power to detect statistically significant relationships between study level covariates such as the prevalence of CAD and inclusion of dialysis and diagnostic accuracy of s/hsTrop was limited due to the relatively small number of studies. The effect of time elapsed between symptom onset to presentation and diagnostic accuracy could not be explored in the present analysis.

**Conclusion**

s/hsTrop assays have excellent diagnostic accuracy for AMI on initial presentation at the currently recommended cut-off of 99th percentile. At a cut-off of LOD, s/hsTrop provides excellent sensitivity for AMI but may not be ideal for risk-free rapid exclusion for ACS. There is no conclusive evidence that s/hsTrop assays outperform conventional Trop assays when a cut-off of 99th percentile is used for the latter. Studies evaluating clinical endpoints and cost-effectiveness
are needed before accepting these assays in routine clinical practice.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Supplementary materials

Table S1 Characteristics of studies reporting diagnostic accuracy of high-sensitive troponin assays using conventional troponin in the reference standard

<table>
<thead>
<tr>
<th>Study</th>
<th>Enrollment period</th>
<th>Sample size</th>
<th>Age (years)*</th>
<th>Males (%)</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aldous et al†</td>
<td>2006–2007</td>
<td>332</td>
<td>64.3</td>
<td>60.2</td>
<td>Consecutive patients attending ED and having suspicion of ACS that serial EKG and Trop were deemed necessary</td>
</tr>
<tr>
<td>Aldous et al†</td>
<td>2007–2010</td>
<td>939</td>
<td>65</td>
<td>59.7</td>
<td>Consecutive patients &gt;18 years with symptoms suggestive of ACS presenting to ED between 5.30 am and 8 pm</td>
</tr>
<tr>
<td>Apple et al‡</td>
<td>NR</td>
<td>371</td>
<td>54</td>
<td>60</td>
<td>Consecutive patients presenting with symptoms suggestive of ACS admitted through the ED to rule in or rule out AMI</td>
</tr>
<tr>
<td>Apple et al‡</td>
<td>2005–2006</td>
<td>381</td>
<td>54</td>
<td>NR</td>
<td>Patients who presented with symptoms suggestive of ACS and were admitted through the ED to rule in or rule out AMI</td>
</tr>
<tr>
<td>Body et al§</td>
<td>2006–2007</td>
<td>703</td>
<td>58.6</td>
<td>61.2</td>
<td>Patients &gt;25 years presenting to ED and had chest pain within the previous 24 hours that the initial treating physician suspected may be cardiac in nature</td>
</tr>
<tr>
<td>Casals et al§</td>
<td>NR</td>
<td>120</td>
<td>67.6</td>
<td>73</td>
<td>Patients presenting with acute chest pain</td>
</tr>
<tr>
<td>Christ et al†</td>
<td>2009</td>
<td>137</td>
<td>66</td>
<td>64</td>
<td>Consecutive patients with acute chest pain of possible coronary origin presented to the ED</td>
</tr>
<tr>
<td>Eggers et al§</td>
<td>2000–2003</td>
<td>360</td>
<td>66.8</td>
<td>65.6</td>
<td>Patients admitted to coronary care unit with chest pain lasting ≥15 minutes within the last 24 hours (FAST II-study), or the last 8 hours (FASTER I-study)</td>
</tr>
<tr>
<td>Freund et al§</td>
<td>2005–2007</td>
<td>317</td>
<td>57</td>
<td>65</td>
<td>Consecutive patients &gt;18 years presented to the ED with chest pain suggestive of ACS with the onset or peak within the previous 6 hours</td>
</tr>
<tr>
<td>Keller et al¹⁰</td>
<td>2007–2008</td>
<td>1,818</td>
<td>61.4</td>
<td>66.4</td>
<td>All patients between 18 and 85 years presenting with acute angina pectoris or equivalent symptoms</td>
</tr>
<tr>
<td>Keller et al¹¹</td>
<td>2007–2008</td>
<td>1,818</td>
<td>61.4</td>
<td>66.4</td>
<td>All patients between 18 and 85 years presenting with acute angina pectoris or equivalent symptoms</td>
</tr>
<tr>
<td>Kurz et al¹²</td>
<td>2008</td>
<td>94</td>
<td>65.6</td>
<td>67</td>
<td>Consecutive patients with symptoms suggestive of ACS admitted to the Chest Pain Unit</td>
</tr>
<tr>
<td>Melki et al¹³</td>
<td>2006–2008</td>
<td>233</td>
<td>65</td>
<td>67</td>
<td>Consecutive patients with chest pain or other symptoms suggestive of ACS within 12 hours admitted to coronary care unit</td>
</tr>
<tr>
<td>Exclusion criteria</td>
<td>Adjudication of diagnosis</td>
<td>s/hTrop assay used</td>
<td>Conventional Trop assay and cut-off used</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------</td>
<td>-------------------</td>
<td>------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18 years old, inability to obtain frozen sample</td>
<td>By two cardiologists based on history, Trop and investigations (including stress test and angiogram) largely in accordance with ACC/AHA guidelines and ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>hsTrop T (Roche)</td>
<td>Architect Trop I 2nd generation (Abbott Laboratories) at 0.028 μg/L (99th percentile)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>By one of the two physicians based on Trop I plus rise or fall pattern of at least 20%, objective evidence of ischemia, or significant CAD on angiogram</td>
<td>hsTrop T (Roche)</td>
<td>Architect Trop I (Abbott Laboratories) at 0.03 μg/L (10% CV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up information not available</td>
<td>By records review in accordance with ESC/ACC/AHA redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>Advia Centaur Trop I Ultra (Siemens Healthcare Diagnostics)</td>
<td>Dade Behring Dimension or Stratus CS at 0.1 μg/L (99th percentile)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inability to obtain second sample</td>
<td>By records review in accordance with ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>VITROS Trop I-ES (Ortho-Clinical Diagnostics)</td>
<td>Dade Behring Dimension or Stratus CS at 0.1 μg/L (99th percentile)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal failure requiring dialysis, trauma with suspected myocardial contusion, or another medical condition mandating hospital admission</td>
<td>By two independent investigators who had all clinical, laboratory, and imaging data available for review, largely in accordance with ESC/ACC/AHA/WHF definition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>hsTrop T (Roche)</td>
<td>4th generation Trop T (Roche) at 10 ng/L (99th percentile)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NR</td>
<td>By clinical, EKG, and enzymatic findings according to ESC/ACC redefinition of MI&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Advia Centaur Trop I Ultra (Siemens Healthcare Diagnostics)</td>
<td>AccuTni Access 2 (Beckman Coulter) at 0.09 μg/L (10% CV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NR</td>
<td>By two independent consultants based on history, Trop, and investigations (including stress test and angiogram) largely in accordance with ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>hsTrop T (Roche)</td>
<td>4th generation Trop T (Roche) at 0.04 μg/L (10% CV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>By independent endpoint evaluators in accordance with ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>hs Trop T (Roche)</td>
<td>Stratus CS (Siemens Healthcare Diagnostics) at 0.07 μg/L (99th percentile)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with acute or chronic kidney failure requiring dialysis</td>
<td>By two ED physicians after reviewing all medical records from presentation to 30 days in accordance with ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>hsTrop T (Roche)</td>
<td>Trop I (Siemens Healthcare Diagnostics) at 0.14 μg/L (10% CV) and Trop I (Beckman Coulter) at 0.06 μg/L (10% CV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major surgery or trauma within the previous 4 weeks, pregnancy, intravenous drug abuse, and anemia (hemoglobin level &lt; 10 g/dL)</td>
<td>By two independent cardiologists after reviewing all available clinical, laboratory, and imaging findings in accordance with current guidelines</td>
<td>Advia Centaur Trop I Ultra (Siemens Healthcare Diagnostics)</td>
<td>Trop T (Roche) at 0.03 ng/mL (10% CV) or Dimension RxL Trop I (Siemens Healthcare Diagnostics) 0.14 ng/dL (10% CV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major surgery or trauma within the previous 4 weeks, pregnancy, intravenous drug abuse, and anemia (hemoglobin level &lt; 10 g/dL)</td>
<td>By two independent cardiologists based on all available clinical, laboratory, and imaging findings according to ESC/ACC/WHF redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>Architect STAT</td>
<td>Trop T (Roche) at 0.03 ng/mL (10% CV) or Dimension RxL Trop I (Siemens Healthcare Diagnostics) 0.14 ng/dL (10% CV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI, chronic kidney disease</td>
<td>Using ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>hsTrop T (Roche)</td>
<td>4th generation Trop T (Roche) at 0.03 μg/L (10% CV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>By two physicians with access to all patients’ data in accordance with ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;14&lt;/sup&gt;</td>
<td>hsTrop T (Roche)</td>
<td>4th generation Trop T (Roche) at 0.04 μg/L (10% CV) or Stratus CS Trop I (Dade Behring) at 0.1 μg/L (10% CV)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### Table S1 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Enrollment period</th>
<th>Sample size</th>
<th>Age (years)*</th>
<th>Males (%)</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reiter et al 14</td>
<td>2006–2009</td>
<td>1,098</td>
<td>64</td>
<td>67</td>
<td>Consecutive patients presenting to the ED with chest pain suggestive of AMI with onset or peak within the last 12 hours</td>
</tr>
<tr>
<td>Schreiber et al 15</td>
<td>2005–2006</td>
<td>465</td>
<td>67</td>
<td>49.2</td>
<td>Patients &gt;21 years presenting to ED with suspected ACS during weekdays between 9 am and 5 pm</td>
</tr>
<tr>
<td><strong>Studies reporting ACS only</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bhardwaj et al 16</td>
<td>2006</td>
<td>318</td>
<td>58.3</td>
<td>53.8</td>
<td>Patients &gt;21 years presenting to ED with symptoms suggestive of ACS</td>
</tr>
<tr>
<td>Zuily et al 17</td>
<td>2009</td>
<td>87</td>
<td>60</td>
<td>64</td>
<td>Consecutive patients admitted to Intensive Care Unit for suspected ACS</td>
</tr>
</tbody>
</table>

**Note:** *Mean/median.

**Abbreviations:** ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; AMI, acute myocardial infarction; CAD, coronary artery disease; CV, coefficient of variance; ED, emergency department; EKG, electrocardiography; ESC, European Society of Cardiology; ESRD, end-stage kidney disease; s/hsTrop, sensitive/high-sensitive troponin; MI, myocardial infarction; NR, not reported; Trop, troponin; STEMI, ST elevation myocardial infarction; WHF, World Heart Federation; Roche, Hoffman-La Roche Ltd; Siemens, Siemens Healthcare Diagnostics.
<table>
<thead>
<tr>
<th>Exclusion criteria</th>
<th>Adjudication of diagnosis</th>
<th>s/hsTrop assay used</th>
<th>Conventional Trop assay and cut-off used</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESRD on dialysis</td>
<td>By two independent cardiologists based on review of all available medical records in accordance with ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;18&lt;/sup&gt;</td>
<td>hsTrop T (Roche) and Trop I Ultra (Siemens Healthcare Diagnostics)</td>
<td>Abbott-Assym Trop I (Abbott Laboratories) at 0.16 ng/mL, Accu Trop I (Beckmann Coulter) at 0.06 ng/mL, or 4th generation Trop T (Roche) 0.035 ng/mL (all 10% CV)</td>
</tr>
<tr>
<td>STEMI</td>
<td>By two authors based on clinical, Trop, and imaging data in accordance with ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;18&lt;/sup&gt;</td>
<td>hsTrop I (Singulex Ereanna)</td>
<td>Dimension RxL Trop I (Siemens Healthcare Diagnostics) 140 ng/L (10% CV)</td>
</tr>
<tr>
<td>Thrombolytic use, high output state, cirrhosis, dialysis, symptoms relief &gt;2 hours, trauma, infection, malignancy, cocaine use, acute bowel or cerebral ischemia, peripheral artery disease</td>
<td>By investigators at each institution and principal investigator after reviewing medical records using standard criteria recommended by ACC/AHA&lt;sup&gt;19&lt;/sup&gt;</td>
<td>hsTrop I (Singulex Ereanna)</td>
<td>Trop T (Roche) at 0.03 ng/mL (10% CV)</td>
</tr>
<tr>
<td>Cardiac arrest or STEMI</td>
<td>By two cardiologists reviewing all data in accordance with ESC/ACC/AHA/WHF redefinition of MI&lt;sup&gt;18&lt;/sup&gt;</td>
<td>hsTrop T (Roche)</td>
<td>Trop I (Siemens Healthcare Diagnostics) 140 ng/L (10% CV)</td>
</tr>
</tbody>
</table>
Table S2 Characteristics of studies reporting diagnostic accuracy of high-sensitive troponin assays using high-sensitive troponin in the reference standard

<table>
<thead>
<tr>
<th>Study</th>
<th>Enrollment period</th>
<th>Sample size</th>
<th>Age (years)</th>
<th>Males (%)</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Adjudication of diagnosis</th>
<th>s/hsTrop assays</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christ et al</td>
<td>2009</td>
<td>137</td>
<td>66</td>
<td>64</td>
<td>Consecutive patients with acute chest pain of possible coronary origin presented to the ED</td>
<td>NR</td>
<td>By two independent consultants after reviewing all available medical records in accordance with ESC/ACC/AHA/WHF redefinition of MI</td>
<td>hsTrop T (Roche)</td>
<td>0.943</td>
<td>0.696</td>
</tr>
<tr>
<td>Giannitsis et al</td>
<td>2009–2010</td>
<td>503</td>
<td>63</td>
<td>63</td>
<td>Patients presenting to Chest Pain Unit with onset of symptoms within previous 12 hours</td>
<td>STEMI, trauma, major surgery in last 4 months, pregnancy, anemia, kidney failure, aged &lt;18 years</td>
<td>By two cardiologists based on ESC/ACC/AHA/WHF redefinition of MI</td>
<td>hsTrop T (Roche)</td>
<td>0.919</td>
<td>0.681</td>
</tr>
<tr>
<td>Inoue et al</td>
<td>2006–2009</td>
<td>432</td>
<td>67</td>
<td>73</td>
<td>Patients with chest pain lasting &gt;20 minutes in last 24 hours who visited ED via ambulance</td>
<td>Kidney disease, malignant or collagen disorder, C-reactive protein &gt;10 mg/dL</td>
<td>By two senior cardiologists according to ESC/ACC/AHA/WHF redefinition of MI</td>
<td>hsTrop T (Roche)</td>
<td>0.879</td>
<td>0.612</td>
</tr>
<tr>
<td>Kelly</td>
<td>NR</td>
<td>952</td>
<td>61</td>
<td>56.4</td>
<td>Adult patients with nontraumatic chest pain</td>
<td>EKG evidence of ischemia or clear alternate diagnosis</td>
<td>By treating cardiologist with all clinical and investigation data, using 99th percentile cut-off</td>
<td>Trop I Ultra (Siemens Healthcare Diagnostics)</td>
<td>0.767</td>
<td>0.936</td>
</tr>
<tr>
<td>Khan et al</td>
<td>2009–2010</td>
<td>180</td>
<td>58</td>
<td>83</td>
<td>Patients age 35–80 years who presented to ED within 4 hours of chest pain</td>
<td>Cardiomyopathies, myocarditis, heart failure, MI with renal failure</td>
<td>By two independent cardiologists on the basis of clinical, EKG, hsTrop, and angiographic findings according to current guidelines</td>
<td>hsTrop T (Roche)</td>
<td>0.870</td>
<td>0.980</td>
</tr>
<tr>
<td>Lotze et al</td>
<td>2010</td>
<td>142</td>
<td>71.2</td>
<td>53</td>
<td>Consecutive patients with symptoms suggestive of MI presenting to ED</td>
<td>Dialysis</td>
<td>By consensus of attending physician and consultant in accordance with ESC/ACC/AHA/WHF redefinition of MI</td>
<td>hsTrop T (Roche)</td>
<td>0.923</td>
<td>0.535</td>
</tr>
<tr>
<td>Melki et al</td>
<td>2006–2008</td>
<td>233</td>
<td>65</td>
<td>67</td>
<td>Consecutive patients with chest pain or other symptoms suggestive of ACS within 12 hours admitted to coronary care unit</td>
<td>STEMI</td>
<td>By two physicians with access to all patients' data in accordance with ESC/ACC/AHA/WHF redefinition of MI</td>
<td>hsTrop T (Roche)</td>
<td>0.98</td>
<td>0.82</td>
</tr>
<tr>
<td>Olivieri et al</td>
<td>2011</td>
<td>299</td>
<td>85</td>
<td>51</td>
<td>Consecutive patients ≥75 years admitted to ED for chest pain with dyspnea</td>
<td>NR</td>
<td>By ESC guidelines and ESC/ACC/AHA/WHF redefinition of MI</td>
<td>hsTrop T (Roche)</td>
<td>1</td>
<td>0.637</td>
</tr>
<tr>
<td>Scharnhorst et al</td>
<td>NR</td>
<td>137</td>
<td>64</td>
<td>65</td>
<td>Consecutive patients entering ED with suspicion of non-ST elevation ACS</td>
<td>STEMI on arrival</td>
<td>By clinical diagnosis made by attending cardiologist using routinely acquired data and hsTrop cut-off of 0.1 μg/L</td>
<td>Trop I Ultra (Siemens Healthcare Diagnostics)</td>
<td>1</td>
<td>0.87</td>
</tr>
</tbody>
</table>

Notes: @Mean or median; "reported diagnostic accuracy for ACS rather than MI; "the cut-off used was 54.5 ng/L, instead of 99th percentile.

Abbreviations: ACS, acute coronary syndrome; ACC, American College of Cardiology; AHA, American Heart Association; ED, emergency department; EKG, electrocardiography; ESC, European Society of Cardiology; MI, myocardial infarction; NR, not reported; s/hsTrop, sensitive/high-sensitive troponin; STEMI, ST elevation myocardial infarction; Trop, troponin; WHF, World Heart Federation.
Figure S1 Summary plot of individual studies reporting sensitivity and specificity for high-sensitive troponin assays at presentation for acute coronary syndrome.

Abbreviations: CI, confidence interval; FN, false negative; FP, false positive; TN, true negative; TP, true positive.

<table>
<thead>
<tr>
<th>Study</th>
<th>TP</th>
<th>FP</th>
<th>FN</th>
<th>TN</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhardwaj et al</td>
<td>35</td>
<td>27</td>
<td>220</td>
<td>206</td>
<td>0.56 (0.43–0.69)</td>
<td>0.86 (0.81–0.90)</td>
</tr>
<tr>
<td>Keller et al</td>
<td>220</td>
<td>182</td>
<td>182</td>
<td>591</td>
<td>0.68 (0.62–0.73)</td>
<td>0.76 (0.73–0.79)</td>
</tr>
<tr>
<td>Zuily et al</td>
<td>33</td>
<td>10</td>
<td>38</td>
<td>27</td>
<td>0.77 (0.61–0.88)</td>
<td>0.86 (0.73–0.95)</td>
</tr>
</tbody>
</table>

Figure S2 QUADAS analysis of methodological quality of included studies.

Abbreviation: QUADAS, Quality Assessment tool for Diagnostic Accuracy Studies.

References


